Boston Scientific (NYSE:BSX) is scheduled to be posting its quarterly earnings results before the market opens on Wednesday, April 24th. Analysts expect Boston Scientific to post earnings of $0.36 per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.
Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, February 6th. The medical equipment provider reported $0.39 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.37 by $0.02. Boston Scientific had a return on equity of 25.92% and a net margin of 17.01%. The firm had revenue of $2.56 billion for the quarter, compared to the consensus estimate of $2.57 billion. During the same quarter in the previous year, the business earned $0.34 earnings per share. The company’s quarterly revenue was up 6.4% on a year-over-year basis. On average, analysts expect Boston Scientific to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.
Shares of NYSE:BSX opened at $35.11 on Monday. Boston Scientific has a 1 year low of $27.91 and a 1 year high of $41.00. The stock has a market cap of $48.82 billion, a P/E ratio of 23.88, a price-to-earnings-growth ratio of 2.06 and a beta of 0.87. The company has a current ratio of 0.76, a quick ratio of 0.54 and a debt-to-equity ratio of 0.55.
In other news, CFO Daniel J. Brennan sold 22,438 shares of the business’s stock in a transaction that occurred on Thursday, February 14th. The stock was sold at an average price of $39.57, for a total value of $887,871.66. Following the sale, the chief financial officer now directly owns 279,183 shares of the company’s stock, valued at approximately $11,047,271.31. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Daniel J. Brennan sold 64,223 shares of the business’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $40.84, for a total value of $2,622,867.32. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 342,352 shares of company stock worth $13,701,434. Insiders own 0.66% of the company’s stock.
A number of research analysts recently issued reports on BSX shares. Zacks Investment Research downgraded Boston Scientific from a “hold” rating to a “sell” rating in a report on Monday, December 31st. Needham & Company LLC restated a “buy” rating and set a $43.00 price target on shares of Boston Scientific in a report on Tuesday, January 8th. Guggenheim restated a “buy” rating and set a $48.00 price target on shares of Boston Scientific in a report on Friday, February 8th. SunTrust Banks restated a “buy” rating and set a $47.00 price target on shares of Boston Scientific in a report on Friday, February 8th. Finally, Canaccord Genuity restated a “buy” rating and set a $45.00 price target on shares of Boston Scientific in a report on Monday, February 11th. Three research analysts have rated the stock with a hold rating, twenty-one have given a buy rating and two have issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $40.72.
Boston Scientific Company Profile
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.
Featured Article: Reverse Stock Split
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.